The Leukemia and Lymphoma Molecular Profiling Project (LLMPP)

[Guest guest]

Greetings,

I'd like to call your attention to a study of interest, and importance,

which I hope you will consider when you have a need for a biopsy. This

study does not require treatment, just consent to take a portion of extra

tissue taken for diagnostic purposes to do advanced micro-array analysis.

http://www.lymphomation.org/study-spotlight-1.htm#unmet

~ Karl

==

Genome Expression Study

Rationale: The observed variability in the clinical course of follicular

lymphoma, along with the diverse range of therapeutic options available,

necessitates accurate prognostic stratification of the individual patient.

Conditions: Lymphoma; Leukemia; Multiple Myeloma; Lymphoid Malignancies

Locations:

Nebraska Medical Center in Omaha,

Southwest Oncology Group centers- see

http://www.swog.org/Visitors/AboutUs.asp#cancercenters

the British Columbia Cancer Agency in Vancouver, Canada;

the Norwegian Radium Hospital in Oslo, Norway;

the University of Würzburg in Würzburg, Germany;

the University of Barcelona in Barcelona, Spain; and

St. Bartholomew's Hospital in London, England.

Background: The Leukemia and Lymphoma Molecular Profiling Project (LLMPP),

a collaboration of researchers in the United States, Canada, and Europe NCI

investigators are working with researchers at the University of Nebraska

Medical Center in Omaha to define the gene expression profiles of all types

of human lymphoid malignancies.

The project is supported by an international collaboration ... The LLMPP

uses " Lymphochip " cDNA (complementary DNA) microarrays, which are enriched

in genes that are expressed in and/or function in lymphocytes. Lymphochip

microarrays allow measurement of the RNA expression levels of the

represented genes. Gene expression profiles developed as a result of this

project may someday be used for disease classification (diagnosis),

prognosis, and therapy selection. Already, results from the LLMPP indicate

that these profiles can improve diagnostic accuracy and provide prognostic

information.

The LLMPP is initiating a multicenter clinical trial to evaluate a lymphoma

diagnostic chip, called LymphDX, which was designed by the company

Affymetrix in collaboration with NCI researchers using LLMPP data. The study

will demonstrate the feasibility of disseminating the LymphDX microarray

technology to all of the participating sites and will also evaluate the

diagnostic utility of the LymphDX chip in a prospective study.

Source: cancer.gov